BCR and Burkitt lymphoma: Given the key role of SYK downstream from the BCR, we treated BL41 cells, a Burkitt’s lymphoma cell line used as a model of GC centroblasts (32), with the SYK inhibitor BAY61-3606 (33), to inhibit BCR signaling.